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Leiomyomas constitute 2.5% of all resected neoplasms of the stomach. They are usually asymptomatic, but may present mucosal
ulceration. Aberrant DNAmethylation is a well-defined epigenetic change in human neoplasms; however, gene-acquired methyla-
tion may not necessarily be related with a malignant phenotype. In this report we analyzed in a gastric leiomyoma, the methylation
status of 84CpGI in tumor suppressor and DNA repair genes. We analyzed the tumor center (TC) and tumor periphery (TP)
separately. We found aberrant methylation in 2/84CpGI in the TC portion, that is, MLH1 and MSH3, and 5/84CpGI in the TP,
that is, MLH1, MSH3, APC, MSH6, and MGMT. The gene with the highest methylation percentage in the TC and TP was MLH1.
Given thatMLH1methylation has been associated withmicrosatellite instability, we analyzed the status of the microsatellite Bat-26.
We found that neither the TC nor the TP presented instability. The methylation ofMLH1,MGMT, and APC has been described in
GISTs, but to the best of our knowledge this is the first time that the methylation of these genes has been associated with gastric
leiomyoma. Further research should be conducted to identify reliable molecular markers that could differentiate between GISTs
and gastric leiomyomas.
1. Introduction
Gastric leiomyomas account for 2.5% of gastric neoplasms.
Although most of them are asymptomatic, patients may
present upper gastrointestinal hemorrhage [1, 2]. Endoscopi-
cally, gastric leiomyomas appear as a large submucosal lesion,
and generally endoscopic biopsies are not deep enough to
be of any diagnostic value [3]. Pathologically, most of these
tumors are composed of spindle cells and display smooth
muscle differentiation. Leiomyomas are defined as being
desmin and actin positive and c-Kit (or CD117) negative
tumors [4].
Tumorigenesis is the result of a multistep process charac-
terized by the accumulation of genetic and epigenetic alter-
ations leading to uncontrolled growth. Among epigenetic
modifications, the most studied event in human neoplasms
is the deregulation of methylation of DNA, giving rise to
widespread changes in the methylome patterns during tumor
progression [5]. The epigenome of tumors is character-
ized by global DNA hypomethylation and by gene-specific
hypermethylation. Gene silencing by CpG islands (CpGI)
hypermethylation in gene promoters can modulate pathways
that control the basic function of the cell by acting directly on
tumor suppressor genes and caretaker genes and indirectly on
oncogenes through their regulators [5].
Gene expression profile studies have demonstrated that
some genes are hypermethylated in gastric GISTs (gastro
intestinal stromal tumors) [6–8], but, to our knowledge,
there is no information of the methylation profile of gastric
leiomyomas.
The objective of this study was to analyze by methyl
specific-multiplex ligation probe amplification (MS-MLPA)
the methylation status of tumor suppressor and DNA repair
genes in a gastric leiomyoma.
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Figure 1: Histopathological images of the gastric leiomyoma analyzed. (a) Intersecting bundles of bland spindle cells in TC (left) and in TP
(right). (b) Strong smooth muscle actin immunoreactivity. (c) Negative immunostain with CD117 (a positive mastocyte is shown as positive
internal control).
2. Case Report
A 63-year-old Hispanic female presented with history of
melena for two days. Upon clinical examination the patient
mentioned that she was treated for H. pylori infection 15
years before. No other constitutional symptoms were present.
Upper gastrointestinal endoscopy was performed, show-
ing an ulcerated submucosal tumor localized on the car-
dial region. Upper endoscopic ultrasonography (EUS) evi-
denced a submucosal lesion, of about 50mm with decreased
echogenicity and homogeneous structure, and no necrotic
areas. The lesion belonged to the muscular layer, and EUS
suggested GIST (gastrointestinal stromal tumor). Multisided
tomography revealed that the lesion was 5 cm and showed no
evidence of other lesions in the abdominal area. The patient
was scheduled for laparoscopic surgery and was discharged
from the hospital eleven days after the operation.
2.1. Histopathology. The histopathological diagnosis for the
submucosal lesion was gastric leiomyoma, characterized by
a proliferation of bland, spindle-shaped cells with elongated
nuclei and eosinophilic fibrillary cytoplasm without necrosis
and atypia (Figure 1). The mitotic index (number of mitoses
per 50 high-power fields, HPF)was<2/50HPF.The immuno-
histochemistry assay indicated diffuse positivity for vimentin,
smooth muscle actin, and desmin and negative staining
for c-Kit/CD117, CD34, cytokeratins AE1/AE2, and S-100.
The morphology of the lesion along with the immunohisto-
chemical features supported the diagnosis of leiomyoma.
2.2. Methylation Analysis. MS-MLPA assay was performed
by kits ME001, ME002, ME003, ME0024, and ME011 accord-
ing to manufacturer’s, MRC-Holland, Amsterdam, The
Netherlands, instructions (http://www.mlpa.com/) on DNA
obtained from the formalin fixed embedded tumor. The
methylation status of 84 CpGIs in 41 cancer related genes was
assessed (Table 1). We have established a cut-off threshold by
considering a region to show methylation if the dosage ratio
was >8% [9]. Due to tumor heterogeneity and in order to
analyze if there were epigenetic differences between different
regions of the tumor, we analyzed separately the tumor center
(TC) and the tumor periphery (TP). We found aberrant
methylation in 2/84 CpGI in the TC portion, that is, one site
localized at 485 nt before the transcription start site (TSS) of
MSH3 andone site at 382 nt beforeTSS ofMLH1. Even though
both genes presented methylation percentages above the
established cut-off level, it is interesting to mention that they
differed significantly: 11.6% and 52.9%, respectively (Figure 2,
green bars). The peripheric portion of the tumor presented a
different profile: 5/84 CpG sites were aberrantly methylated,
from which 2 sites were shared with the center portion, that
is,MSH3 andMLH1, and 3 sites were exclusively methylated
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Table 1: List of genes analyzed in the gastric leiomyoma. Gene
names and gene symbols are according to the HGNC database.
Gene symbol Gene name
APC Adenomatous polyposis coli
ATM Ataxia telangiectasia mutated
BCL2 B-cell CLL/lymphoma 2
BNIP3 BCL2/adenovirus E1B 19 kDa interacting protein 3
BRCA1 Breast cancer 1
BRCA2 Breast cancer 2
CACNA1A Calcium channel, voltage-dependent, P/Q type,
alpha 1A subunit
CACNA1G Calcium channel, voltage-dependent, P/Q type,
alpha 1B subunit




CDKN1B Cyclin-dependent kinase inhibitor 1B
CDKN2A Cyclin-dependent kinase inhibitor 2A
CHFR Checkpoint with forkhead ring finger domains
CREM cAMP responsive element modulator
DAPK1 Death-associated protein kinase 1
DLC1 DLC1 Rho GTPase activating protein
ESR1 Estrogen receptor 1
FHIT Fragile histidine triad
GATA5 GATA binding protein 5
GSTP1 Glutathione S-transferase pi 1
H2AFX H2A histone family, member X
HIC1 Hypermethylated in cancer 1
HLTF Helicase-like transcription factor
ID4 Inhibitor of DNA binding 4, dominant negative
helix-loop-helix protein
MGMT O-6-Methylguanine-DNA methyltransferase
MLH1 MutL homolog 1
MLH3 MutL homolog 3
MSH2 MutS homolog 2
MSH3 MutS homolog 3
MSH6 MutS homolog 6
PAH Phenylalanine hydroxylase
PAX5 Paired box 5
PAX6 Paired box 6
PMS2 PMS2 postmeiotic segregation increased 2
PRDM2 PR domain containing 2, with ZNF domain
PTCH1 Patched 1
PTEN Phosphatase and tensin homolog
PYCARD PYD and CARD domain containing
RARB Retinoic acid receptor beta
RASSF1 Ras association domain family member 1A
RB1 Retinoblastoma 1
Table 1: Continued.
Gene symbol Gene name
RUNX3 Runt-related transcription factor 3
SCGB3A1 Secretoglobin, family 3A, member 1
SFRP4 Secreted frizzled-related protein 4
SFRP5 Secreted frizzled-related protein 5
STK11 Serine/threonine kinase 11
TGIF1 TGFB-induced factor homeobox 1
THBS1 Thrombospondin 1
TIMP3 TIMP metallopeptidase inhibitor 3
TP53 Tumor protein p53
TP73 Tumor protein p73
TWIST1 Twist family bHLH transcription factor 1
VHL Von Hippel-Lindau tumor suppressor

















Figure 2: Genes methylated in a gastric leiomyoma. Grey bars
represent the genes methylated in the tumor periphery and green
bars represent the genes methylated in the tumor center.
in the tumor periphery, that is, MSH6, MGMT, and APC
(Table 2). As a control, MS-MLPA assay was performed
in normal tissue (i.e., leucocytes of healthy patients); we
determined that there was no aberrant methylation in the
regions analyzed. The percentages of methylation in the
TP were 10.8%, 77%, 14.3%, 9.5%, and 27.7%, respectively
(Figure 2, grey bars). Even though the methylated genes
differed between the TC and the TP, it is interesting to
mention that MLH1 was shared by both and presented the
highest percentage of methylation (52.9% and 77%, resp.).
To analyze whether methylation affected gene expression,
we performed qRT-PCR assays on 2 cell lines (MDA-MB231
and MCF-7) which presented different percentages of APC
promotermethylation (0%and 52%, resp.); we confirmed that
the methylation of APC on the CpG site −21 nt before TSS
reduces gene expression (data not shown). The methylation
of MLH1 at 382 nt before TSS has been previously shown to
provoke downregulation of gene expression [10].
Given that MLH1 methylation is associated with mic-
rosatellite instability (MSI) in sporadic endometrial and
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Table 2: List of methylated genes in the gastric leiomyoma studied. Gene names and gene symbols are according to the HGNC database;
CpG site locations are mentioned based on the MRC-Holland data sheets. TP indicates tumor periphery and TC tumor center.
Gene symbol Name CpG location Sample Mehtylation %
APC Adenomatous polyposis coli 21 nt before TSS TP 27.7
TC 0
MGMT O-6-Methylguanine-DNAMethyltransferase 233 nt after TSS TP 9.5
TC 0
MSH6 mutS homolog 6 317 nt before TSS TP 14.3
TC 0
MLH1 MutL Homolog 1 382 nt before TSS TP 77.6
TC 59.2
MSH3 mutS homolog 3 485 nt before TSS TP 10.8
TC 11.6
TSS: transcription start site. nt: nucleotide.
colorectal cancers [11, 12], we decided to analyze MSI in the
gastric leiomyoma. To evaluate MSI, we analyzed by PCR
the status of the mononucleotide microsatellite Bat-26 in
the tumor center and periphery. This microsatellite has been
shown to be highly efficient and sensitive to determine MSI-
H when used as a single marker [13, 14]. Interestingly, Bat-
26 was stable in the TC as well as in the TP portion of the
gastric leiomyoma analyzed. When we tested Bat-26 status
in 5 nontumoral tissues and in peripheral blood of healthy
patients, none of these tissues presented Bat-26 instability.
3. Discussion
The onset and progression of tumorigenesis involves a cas-
cade of genetic and/or epigenetic events. Results from recent
investigations have shown that DNA methylation profiles
contain tumor type-specific signatures which, in the future,
could serve as biomarkers for clinical outcome [15]. Hyper-
methylation at the promoter region of several genes has been
shown to be an important mechanism in gene silencing.
However, gene-acquired methylation may not necessarily be
related with malignant phenotype [16, 17]. In this report, we
show that a gastric leiomyoma, considered a benign disease,
presents methylation in 2–5 of 84 analyzed CpGI, varying in
different tumor parts.
The methylation percentage in the overall sample varied
widely (from 9.5% to 77%) for the different genes (Figure 1).
This wide-ranging methylation levels could be indicating
that the aberrant hypermethylation occurs at different sites
and times, and, therefore, probably the genes with higher
methylation levels (such as MLH1 or APC) were the first
ones to be epigenetically altered during tumoral progression.
Considering thatMLH1 presents a highmethylation percent-
age, we hypothesize that its methylation could be an initial
epigenetic event during gastric leiomyoma formation.
Given that MLH1 methylation is associated with MSI
in several tumors [11, 12], we analyzed the status of the
mononucleotide microsatellite Bat-26. As we mentioned
before, neither the TC nor the TP portion presented Bat-26
instability. We speculate that the gastric leiomyoma analyzed
is not MSI-H due to Bat-26 stability, but we cannot discard
MSI-L or MSI-S. It is interesting to mention that the fact that
MLH1 ismethylated andMSI is stable has been also described
by other authors and several hypotheses have been proposed.
For example, studies performed by Esteller and colleagues
on endometrial atypical hyperplasia concluded that MLH1
promoter methylation is an early event and in some cases
may precede a detectable MSI phenotype [18]. Therefore, a
possible explanation could be that the leiomyoma presents
MLH1 methylation as an early event, lacking yet MSI signs.
In another work performed by Kanaya et al. the authors
studied the region 700 bp upstreamofMLH1 promoter region
covering 48CpG sites; they classified the methylation status
as full (over 80% of CpGsweremethylated), partial (10–80%),
or nonmethylation (less than 10%). The authors concluded
that the degree, rather than region-specific methylation of
CpG islands, is critical for MSI phenotype [19].
The genes found methylated in the gastric leiomyoma
play different functions in the cell: MLH1, MSH3, MGMT,
andMSH6 participate in DNA repair functions whereasAPC
gene participates in cell proliferation. The methylation of
MLH1, MGMT, and APC has been previously described in
GISTs, but to the best of our knowledge this is the first time
that the methylation of these genes has been associated with
gastric leiomyoma, which is considered a benign disease.
Interestingly, we also found that there were differentially
methylated genes between GISTs and the gastric leiomyoma.
For example, in a study performed byHouse et al., the authors
determined that the most frequently methylated genes in
GISTs (in decreasing frequency) are MGMT, p16, RASSF1A,
E-cadherin, and MLH1 [6]. In another report performed by
Saito et al., the authors determined that, besides MLH1 and
MGMT, GISTs also presented methylation in MINT2, p73,
p16, E-cadherin, MINT1, p15, and MINT3. Moreover, the
methylation of RASSF1A progressively increased from small
to malignant GISTs and p16 was specifically methylated in
malignant-prone and malignant GIST [8]. Note that neither
RASSF1, p16, nor p73 is methylated in the studied gastric
leiomyoma. These epigenetic differences between malignant
GISTs and gastric leiomyoma have not been described before.
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To the best of our knowledge this is the first report show-
ing the methylation profile of a gastric leiomyoma. Further
research should be conducted to identify reliable and accurate
molecular markers that could help in the differentiation
between GISTs and gastric leiomyomas.
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